DK0585444T3 - Treatment of hepatomas with somatostatin analogues - Google Patents

Treatment of hepatomas with somatostatin analogues

Info

Publication number
DK0585444T3
DK0585444T3 DK93907029T DK93907029T DK0585444T3 DK 0585444 T3 DK0585444 T3 DK 0585444T3 DK 93907029 T DK93907029 T DK 93907029T DK 93907029 T DK93907029 T DK 93907029T DK 0585444 T3 DK0585444 T3 DK 0585444T3
Authority
DK
Denmark
Prior art keywords
phe
hepatomas
treatment
nal
thr
Prior art date
Application number
DK93907029T
Other languages
Danish (da)
Inventor
Arthur E Bogden
Original Assignee
Biomeasure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomeasure Inc filed Critical Biomeasure Inc
Application granted granted Critical
Publication of DK0585444T3 publication Critical patent/DK0585444T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for treating liver cancer in a mammalian subject. The method includes administering to the subject a composition which contains a therapeutically effective amount of an octapeptide of the following formula: <IMAGE> (I) wherein, A1 is D- beta -Nal or D-Phe; A2 is Phe, pentafluro-Phe, or p-substituted X-Phe where X is a halogen, NH2, NO2, OH, or C1-3 alkyl; A3 is Thr, Ser, Phe, Val, PROPORTIONAL -aminobutyric acid, or Ile; A4 is Thr, beta -Nal, or Trp; and Y is NH2 or OH; or a pharmaceutically acceptable salt or complex thereof.
DK93907029T 1992-02-25 1993-02-25 Treatment of hepatomas with somatostatin analogues DK0585444T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/840,881 US5411943A (en) 1992-02-25 1992-02-25 Hepatoma treatment with somatostatin analogs
PCT/US1993/001679 WO1993016718A1 (en) 1992-02-25 1993-02-25 Hepatoma treatment with somatostatin analogs

Publications (1)

Publication Number Publication Date
DK0585444T3 true DK0585444T3 (en) 2001-09-24

Family

ID=25283467

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93907029T DK0585444T3 (en) 1992-02-25 1993-02-25 Treatment of hepatomas with somatostatin analogues

Country Status (10)

Country Link
US (1) US5411943A (en)
EP (1) EP0585444B1 (en)
JP (1) JPH06507423A (en)
AT (1) ATE203410T1 (en)
CA (1) CA2107773A1 (en)
DE (1) DE69330483T2 (en)
DK (1) DK0585444T3 (en)
ES (1) ES2160595T3 (en)
HK (1) HK1015123A1 (en)
WO (1) WO1993016718A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
US6355613B1 (en) * 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US6150333A (en) * 1998-07-30 2000-11-21 Biomeasure, Inc. Methods of using a somatostatin analogue
US6465613B1 (en) 1998-11-19 2002-10-15 Tulane University Hydrophilic somatostatin analogs
EP1435826A4 (en) 2001-09-21 2009-07-15 Univ Tulane Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
EP1487493B1 (en) * 2002-03-01 2010-01-20 The Administrators of The Tulane Educational Fund Conjugates of cytotoxic agents and biologically active peptides
CA2518406A1 (en) * 2003-03-10 2004-09-23 Biogen Idec Ma Inc. Thiol-mediated drug attachment to targeting peptides
ATE553772T1 (en) * 2007-09-11 2012-05-15 Mondobiotech Lab Ag USE OF LVV HEMORPHIN-6 AND OPTIONAL AF12198 AS THERAPEUTIC AGENT(S).
KR20100061679A (en) * 2007-09-11 2010-06-08 몬도바이오테크 래보래토리즈 아게 Thyrotropin releasing hormone for therapeutic applications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073541A (en) * 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
ATE140237T1 (en) * 1989-12-08 1996-07-15 Univ Tulane OCTAPEPTIDE ANALOGUES OF SOMATOSTATIN WITH THREONINE IN POSITION 6

Also Published As

Publication number Publication date
ES2160595T3 (en) 2001-11-16
EP0585444B1 (en) 2001-07-25
JPH06507423A (en) 1994-08-25
HK1015123A1 (en) 1999-10-08
DE69330483D1 (en) 2001-08-30
US5411943A (en) 1995-05-02
EP0585444A1 (en) 1994-03-09
WO1993016718A1 (en) 1993-09-02
ATE203410T1 (en) 2001-08-15
CA2107773A1 (en) 1993-08-26
EP0585444A4 (en) 1996-01-10
DE69330483T2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
DK0585444T3 (en) Treatment of hepatomas with somatostatin analogues
DK0871440T3 (en) Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
HUP0104579A2 (en) Glp-1 analogues, pharmaceutical compositions comprising thereof and their use
ATE260658T1 (en) PHARMACEUTICAL PREPARATIONS FOR REDUCING RESPIRATORY DEPRESSION
BR0107749A (en) Methods of using a drink composition
KR900003203A (en) Neuropeptide Y antagonists and preparation methods thereof
AU2001277908A1 (en) Medicinal uses of mu-opioid receptor agonists
IE831762L (en) Xanthine derivatives
EA199901075A1 (en) TREATMENT OF RESISTANCE TO INSULIN BY MEANS, INCENTIVE THE SECRETION OF GROWTH HORMONE
GB9519077D0 (en) New heterocyclic compounds
EP1077721B8 (en) Prevention and treatment of hypergastrinemia
BR9915390A (en) Treatment of tumors through administration of compounds that release growth hormone and its antagonists
RU2001116722A (en) METHOD FOR TREATING A TUMOR IN A MAMMAL (OPTIONS)
DE3167826D1 (en) Peptides and their therapeutic use
KR910000794A (en) VIP-analog II
HU896606D0 (en) Process for the preparation of aminoacid derivatives inhibiting enzymes and pharmaceutical compositions thereof
EP0793497A4 (en) Novel enediyne quinone imines and methods of preparation and use thereof
NZ335879A (en) Somatostatin antagonist peptides having a D-amino acid at the second residue
RU2006115606A (en) USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARATION OF THE MEDICINE FOR THE REGULATION OF THE FOLICULAR RESERVE OF THE OVARIES IN WOMEN WHO DOES NOT HAVE MENOPAUSE
DE69220050T2 (en) METHOD FOR INHIBITING FIBROSE
ES8701784A1 (en) V1-vasopressin antagonists.
RU97101109A (en) APPLICATION OF GABAPENTIN FOR TREATMENT OF FEAR AND PANIC CONDITIONS
KR880013902A (en) Amino acid derivatives
DK0745093T3 (en) Novel oligopeptides with affinity for opioid receptors
JPS57176940A (en) Novel color-developing peptide derivative